Johnson & Johnson vs Kymera Therapeutics, Inc. — Stock Comparison

JNJ
Johnson & Johnson
$227.19
▼ 1.16%
vs
KYMR
Kymera Therapeutics, Inc.
$80.71
▼ 0.44%
Q·Score Winner
Johnson & Johnson
JNJ7.1/10vs 5.8/10

Q·Score Breakdown

7.1
Bullish
Overall
5.8
Neutral
9.3
Quality
1.7
6.5
Health
8.2
5.1
Growth
6.1
7.3
Valuation
6
6.5
Sentiment
8.9
JNJ

High-quality business with 26% return on equity and 22% profit margins.

earnings contracting 53% year-over-year.

KYMR

96% of 23 covering analysts have a positive rating.

low return on equity (-27%).

Analyst Consensus

BUY
Target $252.42 (+11.1%)
24 analysts
BUY
Target $118.86 (+47.3%)
21 analysts

Fundamentals

JNJ
KYMR
26.3×
Trailing P/E
17.9×
Forward P/E
-19.9×
21.8%
Profit Margin
0.0%
68.0%
Gross Margin
0.0%
26.4%
ROE
-27.1%
9.9%
Revenue Growth
55.5%
-52.9%
Earnings Growth
0.33
Beta
Price / Book
$546.9B
Market Cap
$6.6B
$146 – $252
52-Week Range
$28 – $103

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →